Quantcast

Latest Epizyme Inc. Stories

2014-06-10 08:30:25

CAMBRIDGE, Mass., June 10, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company

2014-05-28 08:31:11

CAMBRIDGE, Mass., May 28, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating

2014-05-13 16:28:26

-- Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in May 2014; three proof-of-concept studies ongoing with EPZ-5676 CAMBRIDGE, Mass., May 13, 2014 /PRNewswire/

2014-05-07 08:33:47

CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating

2014-05-07 08:32:14

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/

2014-05-01 08:36:08

CAMBRIDGE, Mass., May 1, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company

2014-04-30 16:31:47

CAMBRIDGE, Mass., April 30, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company

2014-04-24 08:33:54

Patent covers methods of use for small molecule inhibitors in the treatment of NHL, including follicular and diffuse large B-cell lymphomas CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/

2014-04-22 08:32:58

- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets - CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Epizyme, Inc.

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc.


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.